Close Menu

NEW YORK (GenomeWeb) – Illumina and China firm Boai NKY Medical Holdings have partnered to develop next-generation sequencing-based hereditary disease tests in China.

Under the agreement announced on Tuesday, NKY and Illumina will develop an NGS system based on Illumina's MiniSeq system and NKY's library prep kits and analysis software to develop in vitro diagnostics for hereditary kidney disease. The goal is to develop a platform that will meet regulatory criteria of China's National Medical Products Administration.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23
Sponsored by
Qiagen: Nov 16, 2014

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.